Report #2899731

Received Jun 11, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: TX
Recovered: Unknown
Vaccinated: Feb 12, 2026
Onset: Feb 12, 2026
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	3	—	—

Symptoms (1)

Extra dose administered

Symptom narrative

Extra dose administered; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a patient who received Herpes zoster (Shingrix) solution for injection for prophylaxis. Previously administered products included Shingrix (first dose received on 17-OCT-2022) and Shingrix (second dose received on 28-DEC-2022). On 12-FEB-2026, the patient received the 3rd dose of Shingrix. On 12-FEB-2026, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: Extra dose administered). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 04-JUN-2026 The batch number was not provided upon follow-up with the reporter.